Compare TREE & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TREE | DCTH |
|---|---|---|
| Founded | 1996 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 533.1M | 578.4M |
| IPO Year | 2008 | 2015 |
| Metric | TREE | DCTH |
|---|---|---|
| Price | $30.79 | $16.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $71.25 | $22.00 |
| AVG Volume (30 Days) | 458.5K | ★ 685.2K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 443.31 | 107.53 |
| EPS | ★ 1.90 | 0.04 |
| Revenue | ★ $1,117,324,000.00 | N/A |
| Revenue This Year | $19.03 | $24.54 |
| Revenue Next Year | $7.07 | $33.15 |
| P/E Ratio | ★ $16.43 | $428.75 |
| Revenue Growth | ★ 24.12 | N/A |
| 52 Week Low | $29.77 | $8.12 |
| 52 Week High | $77.35 | $17.42 |
| Indicator | TREE | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 31.74 | 66.18 |
| Support Level | $29.77 | $10.16 |
| Resistance Level | $39.74 | $17.42 |
| Average True Range (ATR) | 1.30 | 0.82 |
| MACD | -0.01 | 0.18 |
| Stochastic Oscillator | 1.90 | 86.98 |
LendingTree Inc. is a U.S.-based company that mainly operates an online loan marketplace. The company offers online tools and resources to help consumers find loans or other credit-based products, including mortgage loans, reverse mortgages, home equity loans, personal loans, auto loans, credit cards, student loans, small business loans, and various related products. It provides consumers with direct access to a wide array of lenders. The company has three reportable segments: Home, Consumer, and Insurance. It generates match fees by connecting consumers with lenders and closing fees from lenders when a transaction is finalized. The company conducts business solely in the United States.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.